Sažetak sa skupa
https://doi.org/10.26800/LV-142-supp5-20
Efficacy of a fixed combination of insulin degludec and GLP-1 receptor agonist liraglutide (Xultophy) in patient with type 2 diabetes
Ivona Ćudina
; School of Medicine, University of Zagreb, Zagreb, Croatia
Lester Toni Dobrić
; School of Medicine, University of Zagreb, Zagreb, Croatia
Dario Rahelić
; Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, Zagreb, Croatia
Spomenka Ljubić
; School of Medicine, University of Zagreb, Zagreb, Croatia, Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, Zagreb, Croatia
Sažetak
The fixed combination of insulin degludec and liraglutide- Xultophy is a newer therapy available for treatment of type 2 diabetes (DM2). Insulin degludec is an ultralong-basal insulin analogue and liraglutide is a glucagon-like peptide-1 receptor agonist. In this case we monitor values of HbA1c as a marker of glycemia regulation and predictor of vascular incidents, but also fasting glucose, HDL, LDL and triglycerides were observed.
Ključne riječi
DM2; HbA1c; insulin degludec; liraglutide
Hrčak ID:
251663
URI
Datum izdavanja:
27.1.2021.
Posjeta: 787 *